文献速递淋巴瘤造血干细胞移植与细胞治疗

侵袭性T细胞淋巴瘤:2021年诊断、风险分层与治疗进展

Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and management.
PubMed 文献 · Am J Hematol · 2021-06-26

本文综述侵袭性T细胞淋巴瘤的诊断、风险分层与治疗进展。基因表达谱有助于PTCL-nos与ALCL等亚型的诊断和预后判断,突变分析正被纳入新药临床试验以评估疗效生物标志物。靶向药物与免疫治疗(包括allo-SCT、检查点抑制剂、双特异性抗体及CAR-T)处于不同临床研究阶段。

要点

  • 基因表达谱可用于PTCL-nos和ALCL等亚型的诊断与预后判断
  • 靶向治疗涵盖CD30、CD25、CCR4及PI3K-mTOR、JAK/STAT通路等靶点
  • 异基因干细胞移植仍是多数侵袭性PTCL亚型的治愈性治疗手段

核心结论

  • 侵袭性T细胞淋巴瘤预后仍差,分子分型与靶向、免疫治疗是当前研究重点。

研究设计与样本

  • 综述类文章,围绕外周T细胞淋巴瘤(PTCL)的分子发病机制、靶向治疗与免疫治疗进行汇总。

主要发现

  • 基因表达谱(GEP)可辅助多种PTCL亚型的诊断与预后判断,包括PTCL-nos和间变性大细胞淋巴瘤(ALCL)。
  • 突变分析正被纳入新药临床试验,用于评估各种疗效生物标志物以优化治疗选择。
  • 多种靶向药物处于不同临床试验阶段,包括CD30抗体药物偶联物brentuximab vedotin,以及CD25、CCR4、PI3K-mTOR和JAK/STAT通路抑制等靶点。
  • ALK抑制剂对表达ALK的肿瘤有前景;检查点抑制剂在PTCL中的使用仍有争议,在结外NK/T细胞淋巴瘤和皮肤T细胞淋巴瘤中结果最有前景。
  • 双特异性抗体治疗及CAR-T细胞治疗正在临床试验中。

关键数值与推荐

  • PTCL存在超过27种不同亚型,认识已开始超越组织学差异。
  • 异基因干细胞移植仍是多数侵袭性PTCL亚型的治愈性治疗。

临床怎么用

  • 可借助基因表达谱与突变分析辅助PTCL亚型诊断、预后判断及临床试验中的疗效生物标志物评估。
  • 根据肿瘤特定蛋白或受体表达选择相应靶向药物,并将异基因干细胞移植作为多数侵袭性亚型的治愈性选择。

局限性

  • 原文未报告具体样本量、疗效数值及统计学指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Aggressive T-cell lymphomas continue to have a poor prognosis. There are over 27 different subtypes of peripheral T-cell lymphoma (PTCL), and we are now beginning to understand the differences between the various subtypes beyond histologic variations. MOLECULAR PATHOGENESIS OF VARIOUS SUBTYPES OF PTCL: Gene expression profiling (GEP) can help in diagnosis and prognostication of various subtypes including PTCL-nos and anaplastic large cell lymphoma (ALCL). In addition, mutational analysis is now being incorporated in clinical trials of novel agents to evaluate various biomarkers of response to allow better therapeutic choices for patients. TARGETED THERAPIES: There are many targeted agents currently in various stages of clinical trials for PTCL that take advantage of the differential expression of specific proteins or receptors in PTCL tumors. This includes the CD30 directed antibody drug conjugate brentuximab vedotin. Other notable targets are CD25, CCR4, inhibition of PI3kinase - m TOR and JAK/STAT pathways. The ALK inhibitors are promising for ALK expressing tumors. IMMUNOTHERAPIES: Allogeneic stem cell transplant continues to be the curative therapy for most aggressive subtypes of PTCL. The use of checkpoint inhibitors in the treatment of PTCL is still controversial. The most promising results have been seen in cases of extranodal natural killer cell/T-cell (ENK/T) lymphomas and cutaneous T-cell lymphomas (CTCL). Bispecific antibody based treatments as well as CAR-T cell based therapies are in clinical trials.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zain JM, Hanona P. Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and management. Am J Hematol. 2021. PMID: 34111312. doi:10.1002/ajh.26270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。